Johnson & Johnson Weighs Cancer Drug Pricing Pressure Against New Growth Paths
unknown📝 Article Content
FDA approved DARZALEX FASPRO for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Certain Johnson & Johnson cancer therapies were included in the first CMS drug price negotiation list under the Inflation Reduction Act. Johnson & Johnson submitted its Ottava robotic surgery platform to the FDA for authorization. Johnson & Johnson (NYSE: JNJ), trading at $224.44, is drawing fresh attention as these product and regulatory developments affect its pharma and MedTech...
📄 Summary
FDA approved DARZALEX FASPRO for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Certain Johnson & Johnson cancer therapies were included in the first CMS drug price negotiation list under the Inflation Reduction Act. Johnson & Johnson submitted its Ottava robotic surgery platform to the FDA for authorization. Johnson & Johnson (NYSE: JNJ), trading at $224.44, is drawing fresh attention as these product and regulatory developments affect its pharma and MedTech...